246 related articles for article (PubMed ID: 33111480)
1. Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
Koopman B; Groen HJM; Ligtenberg MJL; Grünberg K; Monkhorst K; de Langen AJ; Boelens MC; Paats MS; von der Thüsen JH; Dinjens WNM; Solleveld N; van Wezel T; Gelderblom H; Hendriks LE; Speel EM; Theunissen TE; Kroeze LI; Mehra N; Piet B; van der Wekken AJ; Ter Elst A; Timens W; Willems SM; Meijers RWJ; de Leng WWJ; van Lindert ASR; Radonic T; Hashemi SMS; Heideman DAM; Schuuring E; van Kempen LC
Oncologist; 2021 Aug; 26(8):e1347-e1358. PubMed ID: 33111480
[TBL] [Abstract][Full Text] [Related]
2. Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles.
Koopman B; van der Wekken AJ; Ter Elst A; Hiltermann TJN; Vilacha JF; Groves MR; van den Berg A; Hiddinga BI; Hijmering-Kappelle LBM; Stigt JA; Timens W; Groen HJM; Schuuring E; van Kempen LC
JCO Precis Oncol; 2020 Nov; 4():393-410. PubMed ID: 35050740
[TBL] [Abstract][Full Text] [Related]
3. Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer.
Ciliberto G; Canfora M; Terrenato I; Agnoletto C; Agustoni F; Amoroso L; Baldassarre G; Curigliano G; Delmonte A; De Luca A; Fiorentino M; Gregorc V; Ibrahim T; Lazzari C; Mastronuzzi A; Pronzato P; Santoro A; Scambia G; Tommasi S; Vingiani A; Giacomini P; De Maria R
J Exp Clin Cancer Res; 2022 Oct; 41(1):305. PubMed ID: 36245005
[TBL] [Abstract][Full Text] [Related]
4. Molecular Tumor Boards: current practice and future needs.
van der Velden DL; van Herpen CML; van Laarhoven HWM; Smit EF; Groen HJM; Willems SM; Nederlof PM; Langenberg MHG; Cuppen E; Sleijfer S; Steeghs N; Voest EE
Ann Oncol; 2017 Dec; 28(12):3070-3075. PubMed ID: 29045504
[TBL] [Abstract][Full Text] [Related]
5. Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan.
Naito Y; Sunami K; Kage H; Komine K; Amano T; Imai M; Koyama T; Ennishi D; Kanai M; Kenmotsu H; Maeda T; Morita S; Sakai D; Watanabe K; Shirota H; Kinoshita I; Yoshioka M; Mamesaya N; Ito M; Kohsaka S; Saigusa Y; Yamamoto K; Hirata M; Tsuchihara K; Yoshino T
JAMA Netw Open; 2022 Dec; 5(12):e2245081. PubMed ID: 36469316
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Treatment Recommendations by Molecular Tumor Boards Worldwide.
Rieke DT; Lamping M; Schuh M; Le Tourneau C; Basté N; Burkard ME; Metzeler KH; Leyvraz S; Keilholz U
JCO Precis Oncol; 2018 Nov; 2():1-14. PubMed ID: 35135153
[TBL] [Abstract][Full Text] [Related]
7. Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations.
Willemsen AECAB; Krausz S; Ligtenberg MJL; Grünberg K; Groen HJM; Voest EE; Cuppen EPJG; van Laarhoven HWM; van Herpen CML
Br J Cancer; 2019 Jul; 121(1):34-36. PubMed ID: 31130724
[TBL] [Abstract][Full Text] [Related]
8. Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer.
Behel V; Noronha V; Choughule A; Shetty O; Chandrani P; Kapoor A; Bondili SK; Bajpai J; Kumar R; Pai T; Bal M; Gurav M; Bapat P; Mittal N; Menon S; Patil V; Menon N; Dutt A; Prabhash K
JCO Glob Oncol; 2022 Jul; 8():e2200030. PubMed ID: 35802838
[TBL] [Abstract][Full Text] [Related]
9. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study.
Perez JK; Kleber J; Rothe M; Mangat P; Garrett-Mayer E; Schilsky RL
JCO Precis Oncol; 2024 Mar; 8():e2300615. PubMed ID: 38564684
[TBL] [Abstract][Full Text] [Related]
10. Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute-Designated Comprehensive Cancer Center.
Jain NM; Schmalz L; Cann C; Holland A; Osterman T; Lang K; Wiesner GL; Pal T; Lovly C; Stricker T; Micheel C; Balko JM; Johnson DB; Park BH; Iams W
Oncologist; 2021 Nov; 26(11):e1962-e1970. PubMed ID: 34390291
[TBL] [Abstract][Full Text] [Related]
11. Practice and Impact of Multidisciplinary Tumor Boards on Patient Management: A Prospective Study.
Charara RN; Kreidieh FY; Farhat RA; Al-Feghali KA; Khoury KE; Haydar A; Nassar L; Berjawi G; Shamseddine A; El Saghir NS
J Glob Oncol; 2017 Jun; 3(3):242-249. PubMed ID: 28717766
[TBL] [Abstract][Full Text] [Related]
12. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
Tafe LJ; Gorlov IP; de Abreu FB; Lefferts JA; Liu X; Pettus JR; Marotti JD; Bloch KJ; Memoli VA; Suriawinata AA; Dragnev KH; Fadul CE; Schwartz GN; Morgan CR; Holderness BM; Peterson JD; Tsongalis GJ; Miller TW; Chamberlin MD
Oncologist; 2015 Sep; 20(9):1011-8. PubMed ID: 26205736
[TBL] [Abstract][Full Text] [Related]
13. Software-Tool Support for Collaborative, Virtual, Multi-Site Molecular Tumor Boards.
Schapranow MP; Borchert F; Bougatf N; Hund H; Eils R
SN Comput Sci; 2023; 4(4):358. PubMed ID: 37131499
[TBL] [Abstract][Full Text] [Related]
14. Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care.
Liu A; Vicenzi P; Sharma I; Orr K; Teller C; Koentz M; Trinkman H; Vallance K; Ray A
Hematol Rep; 2023 Apr; 15(2):244-255. PubMed ID: 37092519
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards.
Rieke DT; de Bortoli T; Horak P; Lamping M; Benary M; Jelas I; Rüter G; Berger J; Zettwitz M; Kagelmann N; Kind A; Fabian F; Beule D; Glimm H; Brors B; Stenzinger A; Fröhling S; Keilholz U
BMC Med; 2022 Oct; 20(1):367. PubMed ID: 36274133
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of ACTE-MTB: A tool to systematically assess the maturity of molecular tumor boards.
Love TM; Anaya DA; Prime MS; Ardolino L; Ekinci O
PLoS One; 2022; 17(5):e0268477. PubMed ID: 35560035
[TBL] [Abstract][Full Text] [Related]
17. Decision-Making in Multidisciplinary Tumor Boards in Breast Cancer Care - An Observational Study.
Schellenberger B; Diekmann A; Heuser C; Gambashidze N; Ernstmann N; Ansmann L
J Multidiscip Healthc; 2021; 14():1275-1284. PubMed ID: 34103928
[TBL] [Abstract][Full Text] [Related]
18. Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures.
Engelhardt M; Ihorst G; Schumacher M; Rassner M; Gengenbach L; Möller M; Shoumariyeh K; Neubauer J; Farthmann J; Herget G; Wäsch R
BMC Cancer; 2021 Feb; 21(1):173. PubMed ID: 33596881
[TBL] [Abstract][Full Text] [Related]
19. Multidisciplinary care in patients with prostate cancer: room for improvement.
Strebel RT; Sulser T; Schmid HP; Gillessen S; Fehr M; Huber U; Pless M; Morant R; Winterhalder R; Cathomas R
Support Care Cancer; 2013 Aug; 21(8):2327-33. PubMed ID: 23529667
[TBL] [Abstract][Full Text] [Related]
20. Improving decision making in multidisciplinary tumor boards: prospective longitudinal evaluation of a multicomponent intervention for 1,421 patients.
Lamb BW; Green JS; Benn J; Brown KF; Vincent CA; Sevdalis N
J Am Coll Surg; 2013 Sep; 217(3):412-20. PubMed ID: 23891067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
